<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=Generator content="Microsoft Word 11 (filtered)">
<title>Hawaii Revised Statutes</title>
<style>
<!--
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Courier New";}
h1
	{margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	font-size:12.0pt;
	font-family:"Courier New";}
h3
	{margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	font-size:12.0pt;
	font-family:"Courier New";}
p.XNotesHeading, li.XNotesHeading, div.XNotesHeading
	{margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	font-size:12.0pt;
	font-family:"Courier New";
	font-weight:bold;}
p.XNotes, li.XNotes, div.XNotes
	{margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Courier New";}
p.Constitution, li.Constitution, div.Constitution
	{margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Courier New";}
p.1Paragraph, li.1Paragraph, div.1Paragraph
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	margin-bottom:.0001pt;
	text-indent:-1.0in;
	font-size:12.0pt;
	font-family:"Courier New";}
p.aSubsection, li.aSubsection, div.aSubsection
	{margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Courier New";}
p.ASubparagraph, li.ASubparagraph, div.ASubparagraph
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.5in;
	margin-bottom:.0001pt;
	text-indent:-1.5in;
	font-size:12.0pt;
	font-family:"Courier New";}
p.iClause, li.iClause, div.iClause
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:2.0in;
	margin-bottom:.0001pt;
	text-indent:-2.0in;
	font-size:12.0pt;
	font-family:"Courier New";}
p.ASubparagraphContd, li.ASubparagraphContd, div.ASubparagraphContd
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.5in;
	margin-bottom:.0001pt;
	text-indent:-1.5in;
	font-size:12.0pt;
	font-family:"Courier New";}
p.1ParagraphContd, li.1ParagraphContd, div.1ParagraphContd
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	margin-bottom:.0001pt;
	text-indent:-1.0in;
	font-size:12.0pt;
	font-family:"Courier New";}
p.RegularParagraphs, li.RegularParagraphs, div.RegularParagraphs
	{margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Courier New";}
span.msoins0
	{text-decoration:underline;}
 /* Page Definitions */
 @page Section1
	{size:8.5in 11.0in;
	margin:1.0in 1.25in 1.0in 1.25in;}
div.Section1
	{page:Section1;}
-->
</style>

</head>

<body lang=EN-US>

<div class=Section1>

<p class=RegularParagraphs>     <b>§346-312.5  Rx plus preferred drug list.</b> 
(a)  The department shall establish an Rx plus preferred drug list that
includes but is not limited to:</p>

<p class=1Paragraph>     (1)  Drugs listed on the State's medicaid preferred
drug list;</p>

<p class=1Paragraph>     (2)  Antipsychotic drugs;</p>

<p class=1Paragraph>     (3)  Antidepressant drugs;</p>

<p class=1Paragraph>     (4)  Chemotherapy drugs;</p>

<p class=1Paragraph>     (5)  Antiretroviral drugs;</p>

<p class=1Paragraph>     (6)  Immunosuppressive drugs; and</p>

<p class=1Paragraph>     (7)  Any other drugs listed on the Rx plus preferred
drug list pursuant to this section.</p>

<p class=RegularParagraphs>     (b)  The<span class=msoins0><span
style='text-decoration:none'> pharmacy and therapeutic committee shall review
and </span></span>recomme<span class=msoins0><span style='text-decoration:none'>n</span></span>d<span
class=msoins0><span style='text-decoration:none'> drugs for placement on the Rx
plus preferred drug list, </span></span>striving<span class=msoins0><span
style='text-decoration:none'> to identify the safest and most efficacious drugs
that are </span></span>available<span class=msoins0><span style='text-decoration:
none'> at the lowest cost.  The committee's </span></span>recommendations<span
class=msoins0><span style='text-decoration:none'> may take into consideration
any of the following </span></span>factors<span class=msoins0><span
style='text-decoration:none'>:</span></span></p>

<p class=1Paragraph><span class=msoins0><span style='text-decoration:none'>     (1)  </span></span>Therapeutic<span
class=msoins0><span style='text-decoration:none'> value for the disease or
condition under treatment;</span></span></p>

<p class=1Paragraph>     (2)  Clinical efficacy;</p>

<p class=1Paragraph>     (3)  Safety;</p>

<p class=1Paragraph>     (4)  Cost; and</p>

<p class=1Paragraph>     (5)  Other relevant factors as determined by the
committee.</p>

<p class=RegularParagraphs><span class=msoins0><span style='text-decoration:
none'>     (c)  When considering categories of drugs designed to treat
specialized chronic medical conditions and diseases, the committee shall
consult with physicians and other health care professionals with specialized
clinical knowledge and expertise in this area, either in their capacity as
consultants serving on a subcommittee of the committee, or as physicians or
pharmacists with a practice or specialty in chronic diseases.</span></span></p>

<p class=RegularParagraphs>     <span class=msoins0><span style='text-decoration:
none'>(d)  The determination of a drug's safety and efficacy shall be
consistent with the standards set forth in the peer-reviewed literature and
other available sources, including but not limited to:</span></span></p>

<p class=1Paragraph><span class=msoins0><span style='text-decoration:none'>     (1)  The
American Hospital Formulary Service Drug Information;</span></span></p>

<p class=1Paragraph><span class=msoins0><span style='text-decoration:none'>     (2)  The
United States Pharmacopoeia Drug Information;</span></span></p>

<p class=1Paragraph><span class=msoins0><span style='text-decoration:none'>     (3)  The
DRUGDEX System; and</span></span></p>

<p class=RegularParagraphs style='margin-left:1.0in;text-indent:-1.0in'><span
class=msoins0><span style='text-decoration:none'>     (4)  The American Medical
Association Drug Evaluations.</span></span></p>

<p class=RegularParagraphs><span class=msoins0><span style='text-decoration:
none'>     (e)  The determination of a drug's net cost shall consider the
pharmacy reimbursement amount authorized under section 346-317, as adjusted by
manufacturer's rebates to be paid to the department.  The committee shall
determine that a drug has no significant clinical or safety advantages over one
or more alternative drugs when used for a given purpose before it may consider
the drug's net cost. [L 2004, c 47, pt of §1; am L 2005, c 22, §20]</span></span></p>

<p class=RegularParagraphs>&nbsp;</p>

<p class=RegularParagraphs>&nbsp;</p>

</div>

</body>

</html>
<center><table border="0" width="90%"><tr>
<td align="left"><a href="/hrscurrent/Vol07_Ch0346-0398/HRS0346/HRS_0346-0312.HTM">Previous</a></td>
<td align="center"><a href=/hrscurrent/Vol07_Ch0346-0398>Vol07_Ch0346-0398</a></td>
<td align="right"><a href="/hrscurrent/Vol07_Ch0346-0398/HRS0346/HRS_0346-0313.HTM">Next</a></td>
</tr></table></center>
